license: cc-by-4.0
language:
- en
pretty_name: RxGrab 2026 Brand-to-Generic Patent Cliff Audit
tags:
- pharmacy
- drug-pricing
- generics
- patent-cliff
- healthcare
size_categories:
- n<1K
RxGrab 2026 Brand-to-Generic Patent Cliff Audit
Aggregated cost-drop, time-to-generic, and stalled-generic audit covering 50 high-volume US prescription drugs across 24 therapeutic categories.
- License: CC-BY 4.0
- DOI: 10.5281/zenodo.20632747
- Source study: https://rxgrab.com/research/brand-to-generic-patent-cliff-2026/
- Author: Vincent Wesley Couey (ORCID 0009-0005-6869-308X) · published via RxGrab (rxgrab.com), part of the Lattice research network.
What's in it
Files: data.json. Main table stalledGenerics (7 rows): brand, generic, category, firstGenericYear, twelveMonthRetainedPct, stallDriver.
Method
Aggregates computed from RxGrab drug-database.json cross-referenced against FDA Orange Book, Drugs@FDA, CMS NADAC public files, GAO and ASPE drug pricing reports, IQVIA Use of Medicines public data, GoodRx public coupon-low prices, and Mark Cuban Cost Plus Drugs catalog. Price-drop percentage compares pre-generic brand cash price to post-generic median cash price 24 months after first ANDA approval. Stalled-generic flag applies where post-generic price retained 50 percent or more of pre-generic brand price for 12 or more months after first launch. Time-to-first-generic measured from FDA Orange Book composition-of-matter patent expiry (or settlement-permitted entry date) to first ANDA approval recorded in Drugs@FDA.
Citation
Couey, V. W. (2026). RxGrab 2026 Brand-to-Generic Patent Cliff Audit [Data set]. RxGrab. https://doi.org/10.5281/zenodo.20632747
CC-BY 4.0 — free to use with attribution. Informational and research use only. Not medical advice; verify against the primary source and a licensed professional before relying on any value. Dated snapshot; verify current values before relying on them.